Joel W. Neal, MD, PhD

In terms of tumor control, treatment with cabozantinib and atezolizumab led to an overall response rate of 19% among patients with advanced non–small cell lung cancer, according to Joel W. Neal, MD, PhD.

Cancer Network presents an exclusive interview with Joel W. Neal, MD, PhD, who discusses some of the most important information to come out of this year’s meeting and talks about the future of lung cancer research.